PTC Therapeutics (PTCT) Misses Q4 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Cuts PTC Therapeutics (PTCT) Target to $8
March 1, 2016 9:13 AM ESTJefferies analyst, Gena Wang, cut her PT on TC Therapeutics (NASDAQ: PTCT) after hearing more color on the RTF letter and German pricing status on the 4Q15 earnings call. Consistent with her thesis, the FDA questioned ataluren effectiveness in DMD leaving... More
RBC Cuts PTC Therapeutics (PTCT) Price Target by Nearly 20%
March 1, 2016 8:54 AM ESTRBC Capital analyst, Simos Simeonidis, cut the PT on PTC Therapeutics (NASDAQ: PTCT) to $9 from $11 after the company disclosed that FDA issued the Refuse-to-File letter because it views both the Phase IIb and the ACT DMD trials as "negative" and not providing "substantial... More
Cowen Downgrades PTC Therapeutics (PTCT) to Market Perform
March 1, 2016 7:27 AM ESTCowen downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $7.98 yesterday.
... More